

Panos Kanavos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2163873/publications.pdf>

Version: 2024-02-01

110
papers

4,022
citations

117625

34
h-index

138484

58
g-index

112
all docs

112
docs citations

112
times ranked

4098
citing authors

#	ARTICLE	IF	CITATIONS
1	Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries. <i>PharmacoEconomics - Open</i> , 2022, 6, 315-328.	1.8	22
2	Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA. <i>Investigational New Drugs</i> , 2022, 40, 798-809.	2.6	18
3	Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 757-768.	2.1	22
4	Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e31.	0.5	6
5	Sin taxes and their effect on consumption, revenue generation and health improvement: a systematic literature review in Latin America. <i>Health Policy and Planning</i> , 2021, 36, 790-810.	2.7	14
6	Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration. <i>Health Policy OPEN</i> , 2021, 2, 100045.	1.5	4
7	Does external reference pricing deliver what it promises? Evidence on its impact at national level. <i>European Journal of Health Economics</i> , 2020, 21, 129-151.	2.8	33
8	Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe. <i>Health Policy</i> , 2020, 124, 239-251.	3.0	13
9	Pricing of in-patent pharmaceuticals in the Middle East and North Africa: Is external reference pricing implemented optimally?. <i>Health Policy</i> , 2020, 124, 1297-1309.	3.0	6
10	ICER Value Framework 2020 Update: Recommendations on the Aggregation of Benefits and Contextual Considerations. <i>Value in Health</i> , 2020, 23, 1040-1048.	0.3	13
11	Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. <i>Medical Decision Making</i> , 2020, 40, 830-845.	2.4	8
12	Using a stated preference discrete choice experiment to assess societal value from the perspective of patients with rare diseases in Italy. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 154.	2.7	11
13	International impact of external reference pricing: should national policy-makers care?. <i>European Journal of Health Economics</i> , 2019, 20, 1147-1164.	2.8	9
14	Variations in external reference pricing implementation: does it matter for public policy?. <i>European Journal of Health Economics</i> , 2019, 20, 1375-1397.	2.8	9
15	Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art. <i>European Journal of Health Economics</i> , 2019, 20, 891-918.	2.8	45
16	An EU-wide approach to HTA: An irrelevant development or an opportunity not to be missed?. <i>European Journal of Health Economics</i> , 2019, 20, 329-332.	2.8	17
17	Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries. <i>Health Policy</i> , 2019, 123, 118-129.	3.0	6
18	Health related quality of life aspects not captured by EQ-5D-5L: Results from an international survey of patients. <i>Health Policy</i> , 2019, 123, 159-165.	3.0	42

#	ARTICLE	IF	CITATIONS
19	Comment on: "Does MCDA Trump CEA?" Applied Health Economics and Health Policy, 2019, 17, 123-124.	2.1	3
20	Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey. Future Oncology, 2018, 14, 1701-1710.	2.4	26
21	Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. European Journal of Health Economics, 2018, 19, 123-152.	2.8	198
22	Using IMPRESS to guide policy change in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1251-1255.	3.0	15
23	DIFFERENTIATION OF HEALTH-RELATED QUALITY OF LIFE OUTCOMES BETWEEN FIVE DISEASE AREAS: RESULTS FROM AN INTERNATIONAL SURVEY OF PATIENTS. International Journal of Technology Assessment in Health Care, 2018, 34, 498-506.	0.5	14
24	Managing Risk and Uncertainty in Health Technology Introduction: The Role of Managed Entry Agreements. Global Policy, 2017, 8, 84-92.	1.7	46
25	PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA. Retina, 2017, 37, 886-895.	1.7	58
26	Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries. Value in Health, 2017, 20, 919-926.	0.3	26
27	Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework. Social Science and Medicine, 2017, 188, 137-156.	3.8	135
28	Health Care after the Great Recession: Financing Options for Sustainable and High-quality Health Systems. Global Policy, 2017, 8, 5-6.	1.7	0
29	Resource Allocation and Priority Setting in Health Care: A Multi-criteria Decision Analysis Problem of Value?. Global Policy, 2017, 8, 76-83.	1.7	47
30	The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. Pharmacoeconomics, 2017, 35, 1271-1285.	3.3	94
31	Is the Funding of Public National Health Systems Sustainable over the Long Term? Evidence from Eight OECD Countries. Global Policy, 2017, 8, 7-22.	1.7	9
32	Towards High Quality Health Care and Sustainable Financing – the Role of Health Care Programmes. Global Policy, 2017, 8, 46-59.	1.7	2
33	Strategic procurement and international collaboration to improve access to medicines. Bulletin of the World Health Organization, 2017, 95, 720-722.	3.3	9
34	Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. BMC Medical Informatics and Decision Making, 2017, 17, 149.	3.0	23
35	Socioeconomic costs and health-related quality of life in juvenile idiopathic arthritis: a cost-of-illness study in the United Kingdom. BMC Musculoskeletal Disorders, 2016, 17, 321.	1.9	23
36	Critique of the American Society of Clinical Oncology Value Assessment Framework for Cancer Treatments: Putting Methodologic Robustness First. Journal of Clinical Oncology, 2016, 34, 2935-2936.	1.6	14

#	ARTICLE	IF	CITATIONS
37	SCIENTIFIC AND SOCIAL VALUE JUDGMENTS FOR ORPHAN DRUGS IN HEALTH TECHNOLOGY ASSESSMENT. International Journal of Technology Assessment in Health Care, 2016, 32, 218-232.	0.5	30
38	Impact and Costs of Pharmaceuticals and Biotechnology. , 2016, , 107-187.		0
39	Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. European Journal of Health Economics, 2016, 17, 31-42.	2.8	50
40	Social/economic costs and health-related quality of life in patients with scleroderma in Europe. European Journal of Health Economics, 2016, 17, 109-117.	2.8	28
41	Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. European Journal of Health Economics, 2016, 17, 19-29.	2.8	59
42	Social/economic costs and quality of life in patients with haemophilia in Europe. European Journal of Health Economics, 2016, 17, 53-65.	2.8	53
43	Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe. European Journal of Health Economics, 2016, 17, 7-18.	2.8	38
44	Social/economic costs and health-related quality of life in patients with histiocytosis in Europe. European Journal of Health Economics, 2016, 17, 67-78.	2.8	16
45	Response to: Comment on the implications of external price referencing of pharmaceuticals in Middle East countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 15-16.	1.4	3
46	Mapping research activity on mental health disorders in Europe: study protocol for the Mapping_NCD project. Health Research Policy and Systems, 2016, 14, 39.	2.8	5
47	Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe. European Journal of Health Economics, 2016, 17, 43-52.	2.8	35
48	Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. European Journal of Health Economics, 2016, 17, 89-98.	2.8	41
49	Direct cost of pars plana vitrectomy for the treatment of macular hole, epiretinal membrane and vitreomacular traction: a bottom-up approach. European Journal of Health Economics, 2016, 17, 991-999.	2.8	6
50	Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment. Pharmacoeconomics, 2016, 34, 435-446.	3.3	65
51	Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study. Health Policy, 2016, 120, 35-45.	3.0	39
52	Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom. BMC Health Services Research, 2015, 15, 428.	2.2	42
53	A comparative analysis of coverage decisions for outpatient pharmaceuticals: Evidence from Denmark, Norway and Sweden. Health Policy, 2015, 119, 203-211.	3.0	11
54	Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy, 2015, 119, 964-979.	3.0	200

#	ARTICLE	IF	CITATIONS
55	Clinical, Ethical, and Socioeconomic Considerations for Prescription Drug Use During Pregnancy in Women Suffering From Chronic Diseases. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 947-956.	1.6	2
56	Implications of external price referencing of pharmaceuticals in Middle East countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 993-998.	1.4	29
57	Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. <i>Social Science and Medicine</i> , 2015, 124, 39-47.	3.8	126
58	RESPONSIVENESS OF THE EQ-5D TO CLINICAL CHANGE: IS THE PATIENT EXPERIENCE ADEQUATELY REPRESENTED?. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 10-19.	0.5	44
59	Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States. <i>Health Policy</i> , 2014, 118, 229-241.	3.0	33
60	Acquiring Pharmaceutical Industry Assets in the UK: 1Â+Â1Â=Â1?. <i>Pharmaceutical Medicine</i> , 2014, 28, 245-248.	1.9	2
61	An in-depth analysis of pharmaceutical regulation in the Republic of Moldova. <i>Journal of Pharmaceutical Policy and Practice</i> , 2014, 7, 4.	2.4	8
62	Parallel Trade and Pharmaceutical Prices: A Gameâ€theoretic Approach and Empirical Evidence from the European Union. <i>World Economy</i> , 2014, 37, 856-880.	2.5	7
63	Preferences on Policy Options for Ensuring the Financial Sustainability of Health Care Services in the Future: Results of a Stakeholder Survey. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 639-652.	2.1	13
64	Availability of medical supplies during the 2010 Pakistan floods. <i>The Lancet Global Health</i> , 2013, 1, e13-e14.	6.3	6
65	The generics paradox revisited: empirical evidence from regulated markets. <i>Applied Economics</i> , 2013, 45, 3230-3239.	2.2	32
66	SYMPTOMATIC VITREOMACULAR ADHESION. <i>Retina</i> , 2013, 33, 1503-1511.	1.7	81
67	PARS PLANA VITRECTOMY FOR VITREOMACULAR TRACTION SYNDROME. <i>Retina</i> , 2013, 33, 2012-2017.	1.7	94
68	Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New Drugs. <i>Health Affairs</i> , 2013, 32, 753-761.	5.2	82
69	VITREOUS ATTACHMENT IN AGE-RELATED MACULAR DEGENERATION, DIABETIC MACULAR EDEMA, AND RETINAL VEIN OCCLUSION. <i>Retina</i> , 2013, 33, 1099-1108.	1.7	65
70	What Is Wrong with Orphan Drug Policies? Suggestions for Ways Forward. <i>Value in Health</i> , 2012, 15, 1182-1184.	0.3	37
71	Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study. <i>Health Policy</i> , 2012, 108, 19-26.	3.0	38
72	Commonalities and differences in HTA outcomes: A comparative analysis of five countries and implications for coverage decisions. <i>Health Policy</i> , 2012, 108, 167-177.	3.0	72

#	ARTICLE	IF	CITATIONS
73	Health care inequities in north India: role of public sector in universalizing health care. Indian Journal of Medical Research, 2012, 136, 421-31.	1.0	51
74	User charges in health care: evidence of effect on service utilization & equity from north India. Indian Journal of Medical Research, 2012, 136, 868-76.	1.0	24
75	Medical technology procurement in Europe: A cross-country comparison of current practice and policy. Health Policy, 2011, 100, 43-50.	3.0	70
76	The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors. Health Economics Review, 2011, 1, 18.	2.0	25
77	Determinants of branded prescription medicine prices in OECD countries. Health Economics, Policy and Law, 2011, 6, 337-367.	1.8	52
78	Colorectal cancer management and prevention policies in Greece. European Journal of Health Economics, 2010, 10, 27-33.	2.8	6
79	The burden of colorectal cancer: prevention, treatment and quality of services. European Journal of Health Economics, 2010, 10, 1-3.	2.8	4
80	The dynamics of colorectal cancer management in 17 countries. European Journal of Health Economics, 2010, 10, 115-129.	2.8	48
81	Colorectal cancer management in the United Kingdom: current practice and challenges. European Journal of Health Economics, 2010, 10, 85-90.	2.8	9
82	Prescription drug coverage among elderly and disabled Americans: can Medicare's Part D reduce inequities in access?. International Journal of Health Care Finance and Economics, 2010, 10, 203-218.	1.2	4
83	Competition in prescription drug markets: is parallel trade the answer?. Managerial and Decision Economics, 2010, 31, 325-338.	2.5	11
84	Impact of regulation of Community Pharmacies on efficiency, access and equity. Evidence from the UK and Spain. Health Policy, 2010, 95, 245-254.	3.0	36
85	Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP. Globalization and Health, 2009, 5, 19.	4.9	26
86	Competition in off-patent drug markets: Issues, regulation and evidence. Economic Policy, 2008, 23, 499-544.	2.3	92
87	Assessing the economic challenges posed by orphan drugs. International Journal of Technology Assessment in Health Care, 2007, 23, 36-42.	0.5	214
88	Determinants of out-of-pocket pharmaceutical expenditure and access to drugs in Catalonia. Applied Economics, 2007, 39, 541-551.	2.2	19
89	Do generics offer significant savings to the UK National Health Service?. Current Medical Research and Opinion, 2007, 23, 105-116.	1.9	74
90	Product differentiation, competition and regulation of new drugs: the case of statins in four European countries. Managerial and Decision Economics, 2007, 28, 455-465.	2.5	14

#	ARTICLE	IF	CITATIONS
91	Pharmacy discounts on generic medicines in France: is there room for further efficiency savings?. Current Medical Research and Opinion, 2007, 23, 2467-2476.	1.9	30
92	Insurance Coverage and the Heterogeneity of Health and Drug Spending in the United States. Geneva Papers on Risk and Insurance: Issues and Practice, 2006, 31, 669-691.	2.1	7
93	The economics of blood: Gift of life or a commodity?. International Journal of Technology Assessment in Health Care, 2006, 22, 338-343.	0.5	22
94	Centralized Drug Review Processes In Australia, Canada, New Zealand, And The United Kingdom. Health Affairs, 2006, 25, 337-347.	5.2	183
95	Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia. British Journal of Psychiatry, 2005, 187, 137-142.	2.8	25
96	Senior Citizens and the Burden of Prescription Drug Outlays. Applied Health Economics and Health Policy, 2004, 3, 217-227.	2.1	3
97	Reference Pricing For Drugs: Is It Compatible With U.S. Health Care?. Health Affairs, 2003, 22, 16-30.	5.2	91
98	Encouraging the use of generic medicines: implications for transition economies. Croatian Medical Journal, 2002, 43, 462-9.	0.7	112
99	Cross-Border Issues in the Provision of Health Services: Are We Moving towards a European Health Care Policy?. Journal of Health Services Research and Policy, 2000, 5, 231-236.	1.7	15
100	CAN ECONOMIC EVALUATION GUIDELINES IMPROVE EFFICIENCY IN RESOURCE ALLOCATION? The Cases of Portugal, the Netherlands, Finland, and the United Kingdom. International Journal of Technology Assessment in Health Care, 2000, 16, 1179-1192.	0.5	34
101	Health economics: an evolving paradigm. , 2000, 9, 183-190.		29
102	The Single Market for Pharmaceuticals in the European Union in Light of European Court of Justice Rulings. Pharmacoeconomics, 2000, 18, 523-532.	3.3	11
103	Outstanding Regulatory Aspects in the European Pharmaceutical Market. Pharmacoeconomics, 1999, 15, 519-533.	3.3	20
104	Cross border health care in Europe. BMJ: British Medical Journal, 1999, 318, 1157-1158.	2.3	9
105	International Comparisons of Health Care Expenditures: What We Know and What We Do not Know. Journal of Health Services Research and Policy, 1999, 4, 122-126.	1.7	33
106	Financing pharmaceuticals in transition economies. Croatian Medical Journal, 1999, 40, 244-59.	0.7	10
107	Single European Currency and Monetary Union. Pharmacoeconomics, 1998, 13, 9-20.	3.3	5
108	A Prospective View on European Pharmaceutical Research and Development. Pharmacoeconomics, 1998, 13, 181-190.	3.3	3

#	ARTICLE	IF	CITATIONS
109	Will Managed Care Work in Europe?. <i>Pharmacoeconomics</i> , 1997, 11, 297-305.	3.3	8
110	Health policy versus industrial policy in the pharmaceutical sector: the case of Canada. <i>Health Policy</i> , 1997, 41, 241-260.	3.0	26